Bay­er gets green light to sell long-act­ing he­mo­phil­ia A ther­a­py as Roche mus­cles in with Hem­li­bra

Adding an­oth­er com­mer­cial prod­uct to its he­mo­phil­ia port­fo­lio, Bay­er has re­ceived FDA ap­proval for its long-act­ing re­com­bi­nant Fac­tor VI­II re­place­ment ther­a­py for he­mo­phil­ia A — giv­ing it a green light for a field that Roche has be­gun to dom­i­nate with Hem­li­bra.

The fre­quen­cy of treat­ment is key here, Bay­er says. Be­ing ap­proved for a step-wise pro­phy­lax­is dos­ing reg­i­men means that pa­tients will start out with twice-week­ly in­fu­sions but can move on to dose every five days, or even more.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.